Login
Corvus Pharmaceuticals NASDAQ: CRVS
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
| Name | Corvus Pharmaceuticals |
| Ticker | CRVS |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 4.06 |
| 52W Low/High | 1.74 / 5.98 |
| Market cap | 114 M |
| 1Y Total Return |
-28.77%
Weak |
| 1Y Volatility |
110.47%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Details
| Ticker | CRVS |
| Name | Corvus Pharmaceuticals |
| ISIN | US2210151005 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
| Close Price | 4.06 |
| 52W Low/High | 1.74 / 5.98 |
| Market cap | 114 M |
| 1Y Total Return |
-28.77%
Weak |
| 1Y Volatility |
110.47%
High Risk |
| Beta | 2.88 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -2.92 |
| Diluted Earnings / Share | -1.51 |
| ROE | - |
| ROIC | -93.7% |
| Price / Revenue | - |
| Price / Book | 2.8 |
| Price / CF | -3.4 |
| Current Ratio | 4.4 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.06 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Gross Profit |
-
|
-
|
-
|
-
|
-
|
-
|
|
| R&D |
34
|
37
|
40
|
46
|
25
|
-
|
|
| EBITDA |
-44
|
-45
|
-47
|
-54
|
-31
|
-
|
|
| Operating Income |
-45
|
-49
|
-50
|
-56
|
-32
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
30
|
29
|
29
|
21
|
20
|
-
|
|
| EPS exc. Extra |
-1.51
|
-1.57
|
-1.97
|
-2.67
|
-17.21
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
56
|
92
|
127
|
105
|
150
|
-
|
|
| Cash, Eq & Invt ShortTerm |
51
|
86
|
123
|
100
|
145
|
-
|
|
| Total Current Assets |
53
|
88
|
125
|
101
|
146
|
-
|
|
| Total Non-Current Assets |
3
|
5
|
3
|
4
|
4
|
-
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Total Liabilities |
14
|
12
|
8
|
11
|
7
|
-
|
|
| Total Current Liabilities |
12
|
10
|
8
|
10
|
6
|
-
|
|
| Long Term Debt |
2
|
3
|
1
|
1
|
1
|
-
|
|
| Shareholder equity |
42
|
80
|
119
|
94
|
143
|
-
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-35
|
-37
|
-44
|
-45
|
-22
|
-
|
|
| Depreciation |
1
|
1
|
1
|
1
|
0
|
-
|
|
| Cash from Investing |
49
|
5
|
-26
|
83
|
-122
|
-
|
|
| Capex |
0
|
0
|
0
|
1
|
2
|
-
|
|
| Cash from Financing |
0
|
0
|
66
|
0
|
71
|
-
|
|
| Stock Issued |
0
|
0
|
66
|
0
|
71
|
-
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Free Cash Flow |
8
|
-39
|
-76
|
33
|
-
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
4.4
|
9.2
|
16.1
|
10.1
|
26.1
|
-
|
|
| Financial Leverage D/E |
0.06
|
0.04
|
0.00
|
0.00
|
0.00
|
-
|
|
| Return on Capital Avg |
-93.7%
|
-60.5%
|
-74.7%
|
-57.9%
|
-45.2%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available